Motif Bio’s (MTFB) “Buy” Rating Reiterated at Peel Hunt
Several other equities analysts also recently weighed in on MTFB. Northland Capital Partners reissued a buy rating and set a GBX 115 ($1.47) price target on shares of Motif Bio in a research report on Friday, May 4th. Northland Securities reissued a buy rating and set a GBX 115 ($1.47) price target on shares of Motif Bio in a research report on Tuesday, May 8th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of GBX 109.40 ($1.40).
Motif Bio stock opened at GBX 33.58 ($0.43) on Tuesday. Motif Bio has a fifty-two week low of GBX 23.50 ($0.30) and a fifty-two week high of GBX 51.75 ($0.66).
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
Further Reading: Outstanding Shares
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.